NX-1607 (Cbl-b-IN-3) is an oral inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), which is an E3 ubiquitin ligase and a key regulator of T, NK, and dendritic cell activation and suppresses their anti-tumor functions. NX-1607 enhances antigen recall, reduces T cell exhaustion, and increases cytokine production in response to T cell receptor stimulation, thereby […]

NX-1607 (Cbl-b-IN-3) is an oral inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), which is an E3 ubiquitin ligase and a key regulator of T, NK, and dendritic cell activation and suppresses their anti-tumor functions. NX-1607 enhances antigen recall, reduces T cell exhaustion, and increases cytokine production in response to T cell receptor stimulation, thereby […]

DCC-3116 is a selective inhibitor of ULK1/2 that blocks both basal and sotorasib-induced autophagy in KRAS G12C-driven cell lines and exhibits anti-tumor activity.

DCC-3116 is a selective inhibitor of ULK1/2 that blocks both basal and sotorasib-induced autophagy in KRAS G12C-driven cell lines and exhibits anti-tumor activity.

DCC-3116 is a selective inhibitor of ULK1/2 that blocks both basal and sotorasib-induced autophagy in KRAS G12C-driven cell lines and exhibits anti-tumor activity.

DCC-3116 is a selective inhibitor of ULK1/2 that blocks both basal and sotorasib-induced autophagy in KRAS G12C-driven cell lines and exhibits anti-tumor activity.

Pevonedistat hydrochloride (MLN4924 hydrochloride) is a potent and selective inhibitor of NEDD8-activating enzyme (NAE) with an IC50 of 4.7 nM. It disrupts cullin-RING ligase-mediated protein degradation, leading to apoptotic cell death in human tumor cells through the deregulation of S-phase DNA synthesis.

BLU-222 is an oral, potent, and selective inhibitor of cyclin-dependent kinase (CDK) 2 and exhibits significant antitumor activity in the OVCAR-3 CDX model.

BLU-222 is an oral, potent, and selective inhibitor of cyclin-dependent kinase (CDK) 2 and exhibits significant antitumor activity in the OVCAR-3 CDX model.

BLU-222 is an oral, potent, and selective inhibitor of cyclin-dependent kinase (CDK) 2 and exhibits significant antitumor activity in the OVCAR-3 CDX model.